[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glutathione\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glutathione":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637285","phase-2-gingival-hyperpigmentation-treatment-100637285",false,"NCT07595705","Gingival Hyperpigmentation Treatment","Gingival Hyperpigmentation Treatment With Injectable Vitamin C in Conjunction With Glutathione Versus The Conventional Surgical Depigmentation: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nThe selection criteria were done according to Gingival pigmentation index is as follows (Dummett and Bolden)10:\n\n1. Score0:absence of pigmentation\n2. Score1:spotsofbrowntoblackcolororpigments\n3. Score2:browntoblackpatchesbutnotdiffusepigmentation\n4. Score3:diffuse brown to black pigmentation,marginal,and attached.\n\nPatients who have Dummett and Bolden index score 1, 2, or 3 will be included in addition to the following criteria:\n\n1. above 18yrs\n2. systemically free\n3. physiologic gingival hyperpigmentation related to esthetic region\n4. well maintained oral hygiene and willing to undergo minor surgical procedures\n\nExclusion Criteria:\n\n1. systemic diseases associated with pathological hyperpigmentation or improper delayed wound healing (uncontrolled diabetes, autoimmune diseases, etc.)\n2. pregnant and lactating mothers\n3. usage of chlorhexidine or povidone iodine\n4. Local causes (smoking)\n5. periodontal diseases (plaque and non-plaque induced gingivitis or periodontitis)\n6. non compliant patients",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","It is a clinical study conducted to evaluate the effect of vitamin C and Glucathonine injection of pigmented gingival tissue versus surgical removal by scalpel",[27,28,29,30],"Gingival Pigmentation","Depigmentation","Vitamin C","Glutathione",[32,33,34,35],"depigmentation","vit c","glutathione","gingival depigmentation","RECRUITING","2026-05-15",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":40},"2025-08-01",{"date":44,"type":21},"2027-10",{"name":46,"class":47},"Cairo University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100610005","the-impact-of-qualia-gluthathione-on-blood-glutathione-levels-100610005","NCT07221955","The Impact of Qualia Gluthathione+ on Blood Glutathione Levels","Inclusion criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Healthy male and female participants aged 45-75 years\n* Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)\n* Willing to avoid starting new or stopping any existing dietary supplements throughout the study\n\nExclusion criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Adults lacking capacity to consent\n* Active Smokers\n* Diagnosed Diabetics","45 Years","75 Years",{"count":58,"type":21},54,[60],"NA","This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[63,30],"Effects of Qualia Glutathione+ on Blood Glutathione Levels","NOT_YET_RECRUITING","2025-11-12",{"date":67,"type":40},"2025-11-14",{"date":69,"type":21},"2025-12-02",{"date":71,"type":21},"2026-01-25",{"name":73,"class":74},"Qualia Life Sciences","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100584981","phase-1-randomized-trial-of-glutathione-with-anti-pd-1-and-chemotherapy-in-advanced-nsclc-100584981","NCT06896422","Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","Prospective, Randomized Controlled Clinical Trial of Glutathione Combined With PD-1 Antibody and Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma.\n2. Documented disease progression following first-line chemotherapy or chemo-immunotherapy.\n3. Age ≥18 years at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patients with small cell lung cancer or other histological subtypes of lung cancer.\n2. Patients lost to follow-up, who discontinued treatment, or died within one year of diagnosis.\n3. Pregnant or lactating women",{"count":83,"type":21},80,[85],"PHASE1","Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.",[88,89,90,30],"Non-Small Cell Lung Cancer","Chemotherapy","PD1 Antibody","2025-08-06",{"date":93,"type":40},"2025-08-07",{"date":95,"type":40},"2025-06-01",{"date":97,"type":21},"2027-12-31",{"name":99,"class":47},"The First Affiliated Hospital of Zhengzhou University"]